ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
In patients with oncogene-driven advanced non-small cell lung cancer treated with tyrosine kinase inhibitors, ctDNA clearance within 10 weeks of treatment initiation was associated with improved OS and PFS. These patient-level results support the growing evidence that demonstrates a change in ctDNA levels during treatment is associated with clinical benefit. Future prospective trials should include predefined thresholds of molecular response to advance the utility of ctDNA as an early endpoint.
Authors
- Shibing Deng (ORCID: https://orcid.org/0000-0002-2867-263X)
- Jean-François Martini (ORCID: https://orcid.org/0000-0001-8570-1401)
- Diana Merino Vega (ORCID: https://orcid.org/0000-0002-6173-6957)
- Jeff Allen (ORCID: https://orcid.org/0000-0002-0586-3054)
- Carin R. Espenschied (ORCID: https://orcid.org/0000-0001-6108-7785)
- Sameera R. Wijayawardana (ORCID: https://orcid.org/0000-0002-5187-167X)
- Samuel Hong (ORCID: https://orcid.org/0000-0001-7074-0176)
- Névine Zariffa (ORCID: https://orcid.org/0000-0001-7412-2260)
- Antje Hoering (ORCID: https://orcid.org/0000-0002-4709-3027)
- Anna M. Szpurka (ORCID: https://orcid.org/0000-0002-1348-955X)
- Minakshi Guha
- Geoffrey R. Oxnard (ORCID: https://orcid.org/0000-0003-1054-8240)
- Mark Stewart (ORCID: https://orcid.org/0000-0002-4847-0736)
- Dilafruz Juraeva (ORCID: https://orcid.org/0000-0003-0035-3503)
- Gary A. Pestano (ORCID: https://orcid.org/0000-0002-7903-2552)
- Hillary S. Andrews (ORCID: https://orcid.org/0000-0002-0177-2024)
- Nicole Krämer (ORCID: https://orcid.org/0000-0002-8209-9141)
- Li Liu (ORCID: https://orcid.org/0000-0001-8580-3432)
- Emily Goren (ORCID: https://orcid.org/0000-0002-0202-5856)
- Stephanie H. Choi
- Katherine K. Nishimura (ORCID: https://orcid.org/0000-0003-3950-4495)
- Brittany A. McKelvey (ORCID: https://orcid.org/0000-0001-9239-7153)
- Christine K. Ward (ORCID: https://orcid.org/0000-0003-3332-5904)
- Lynne Poole (ORCID: https://orcid.org/0009-0002-9460-1570)
- Adam Rosenthal (ORCID: https://orcid.org/0009-0001-3531-6043)
- Megan Eisele
Institutions
- AstraZeneca (United Kingdom) (GB)
- Boehringer Ingelheim (Germany) (DE)
- Agilent Technologies (United States) (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Eli Lilly (United States) (US)
- Illumina (United States) (US)
- Pfizer (United States) (US)
- Alliance for Decision Education (US)
- Guardant (United States) (US)
- Cancer Research And Biostatistics (US)
- AstraZeneca (Japan) (JP)
- SpectraDynamics (United States) (US)
- Vedantra Pharmaceuticals (United States) (US)
- Merck Serono S.p.A. (Italy) (IT)
- Friends of Cancer Research (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3612
- Citations
- 12
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 11.23
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- EMD Serono